文献速递冠心病心律失常

房颤抗凝合并抗血小板:阿司匹林与P2Y12抑制剂比较

Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation.
PubMed 文献 · Heart · 2021-07-14

基于AFIRE试验中接受利伐沙班联合抗血小板治疗的患者,比较P2Y12抑制剂与阿司匹林的有效性和安全性。共纳入1075例(P2Y12组297例,阿司匹林组778例),主要疗效终点(HR 1.31;95%CI 0.88-1.94;p=0.178)与主要安全终点(HR 0.79;95%CI 0.43-1.47;p=0.456)均无显著差异。

要点

  • 房颤合并稳定冠心病患者,利伐沙班联合P2Y12抑制剂或阿司匹林的心血管事件无显著差异。
  • 两组大出血风险亦无显著差异(HR 0.79;95%CI 0.43-1.47)。
  • 约60%患者使用质子泵抑制剂,两组使用率无显著差异。

核心结论

  • 房颤合并稳定冠心病患者,利伐沙班联合P2Y12抑制剂或阿司匹林,心血管事件和大出血事件均无显著差异。

研究设计与样本

  • 基于AFIRE试验的事后分析,纳入接受利伐沙班联合抗血小板治疗的患者,抗血小板药物由医生决定。
  • 共纳入1075例患者,P2Y12抑制剂组297例,阿司匹林组778例。

主要发现

  • 主要疗效终点(卒中、系统性栓塞、心肌梗死、需血运重建的不稳定心绞痛或全因死亡)两组无显著差异(HR 1.31;95%CI 0.88-1.94;p=0.178)。
  • 主要安全终点(ISTH标准大出血)两组无显著差异(HR 0.79;95%CI 0.43-1.47;p=0.456)。
  • 约60%患者使用质子泵抑制剂,两组使用率无显著差异。

关键数值与推荐

  • 主要疗效终点:卒中、系统性栓塞、心肌梗死、需血运重建的不稳定心绞痛或全因死亡复合终点。
  • 主要安全终点:根据国际血栓与止血学会(ISTH)标准定义的大出血。

临床怎么用

  • 对于房颤合并稳定冠心病患者,在利伐沙班抗凝基础上,选择P2Y12抑制剂或阿司匹林对心血管和出血事件无显著影响。
  • 临床可根据患者具体情况个体化选择抗血小板药物。

局限性

  • 抗血小板药物选择非随机,由医生决定,可能存在选择偏倚。
  • 为AFIRE试验的事后分析,样本量有限,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with coronary artery disease (CAD) and atrial fibrillation (AF) can be treated with multiple antithrombotic therapies including antiplatelet and anticoagulant therapies; however, this has the potential to increase bleeding risk. Here, we aimed to evaluate the efficacy and safety of P2Y12 inhibitors and aspirin in patients also receiving anticoagulant therapy. METHODS: We evaluated patients from the Atrial Fibrillation and Ischaemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial who received rivaroxaban plus an antiplatelet agent; the choice of antiplatelet agent was left to the physician's discretion. The primary efficacy and safety end points, consistent with those of the AFIRE trial, were compared between P2Y12 inhibitors and aspirin groups. The primary efficacy end point was a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularisation or death from any cause. The primary safety end point was major bleeding according to the International Society on Thrombosis and Haemostasis criteria. RESULTS: A total of 1075 patients were included (P2Y12 inhibitor group, n=297; aspirin group, n=778). Approximately 60% of patients were administered proton pump inhibitors (PPIs) and there was no significant difference in PPI use in the groups. There were no significant differences in the primary end points between the groups (efficacy: HR 1.31; 95% CI 0.88 to 1.94; p=0.178; safety: HR 0.79; 95% CI 0.43 to 1.47; p=0.456). CONCLUSIONS: There were no significant differences in cardiovascular and bleeding events in patients with AF and stable CAD taking rivaroxaban with P2Y12 inhibitors or aspirin in the chronic phase. TRIAL REGISTRATION NUMBER: UMIN000016612; NCT02642419.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Fukaya H, Ako J, Yasuda S, et al. Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation. Heart. 2021. PMID: 34261738. doi:10.1136/heartjnl-2021-319321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。